The U.K.'s cost-effectiveness watchdog says it's not planning to recommend a new Crohn's disease treatment from Millennium Pharmaceuticals. The National Institute for Health and Care Excellence (NICE) cited uncertain evidence for the drug, Entyvio, and said it's unlikely it would be a good value for the National Health Service. The draft decision comes despite the Takeda unit's offer of a discount. Report